TaiGen Biotech Raises $37 Million
TaiGen Biotechnology Co., a Taiwan-based drug developer whose lead candidate is a stem cell mobilizer, has raised $37 million in Series C funding. Backers include MPM Capital, National Development Fund, YFY group, Taiwan Sugar Corp., Yao-Hwa Glass Management Commission and Taiwan Global BioFund.
21 January 2009•3 mins read
